Origami Therapeutics, Inc. GTM brain

Origami Therapeutics develops experimental small-molecule protein degraders for neurodegenerative diseases and seeks pharmaceutical development partners.

category

Neurodegenerative disease drug discovery

market profile

  • text: The company is preclinical and its lead focus is Huntington's disease, so commercial treatment availability and efficacy remain unproven.
  • text: Its partnering model targets drug development companies as well as eventual patients and clinicians.

personas

  • title: Pharma business development and licensing lead
    pains:
    • Finding differentiated neuroscience assets with credible translational evidence
    • Managing technical and clinical risk in early-stage partnerships
  • title: Neuroscience research and development leader
    pains:
    • Disease-causing proteins can be difficult to address with conventional inhibitors
    • Candidate molecules must reach the brain and preserve normal protein function
  • title: Huntington's disease clinician or patient advocate
    pains:
    • Progressive disease creates demand for treatments that modify disease rather than only symptoms
    • Preclinical findings may not translate to clinical benefit

icp

  • text: Biopharmaceutical companies with neuroscience or rare genetic disease portfolios and external innovation teams.
  • text: Drug developers able to fund clinical development and commercialize assets are plausible collaboration targets.

message pillars

  • text: Develop disease-modifying protein degraders.
  • text: Aim for selective removal while sparing normal proteins.
  • text: Use small molecules for distribution and manufacturability.

objections

  • objection: Preclinical results may not translate to patients.
    response: Share the stage, model data and clinical milestones without implying efficacy is established.
  • objection: A degrader could affect healthy protein or fail to reach the brain.
    response: Discuss selectivity and brain exposure data under appropriate diligence, with limitations.

competitors

  • name: Arvinas
    why: Develops targeted protein degradation therapeutics.
  • name: Kymera Therapeutics
    why: Develops targeted protein degrader medicines.
  • name: Monte Rosa Therapeutics
    why: Develops molecular glue protein degraders.

influencers

  • name: Beth Hoffman
    url: https://www.linkedin.com/in/bethhoffman
    why: Founder and CEO discussing neuroscience drug discovery and partnerships.

keywords

  • Huntington disease protein degrader
  • neurodegeneration drug discovery
  • small molecule protein degradation
  • mutant huntingtin therapeutics
  • CNS drug development partnership
  • protein misfolding therapeutics

voice

  • scientific
  • mission driven
  • cautious about potential

signals

  • text: A pharma company announces a neuroscience or rare disease licensing mandate.
  • text: An R&D group is investing in targeted protein degradation or Huntington's disease.

pricing

model: unknown

motion

sales_led

channels

  • scientific conferences
  • biopharma partnerships
  • LinkedIn
  • press

confidence

medium

Founders

  • name: Beth Hoffman
    title: Founder
    role: Founder
    bio: At Origami Therapeutics, Dr. Hoffman is creating a new approach to drug discovery for neurodegenerative diseases. Prior to Origami, she was a Research & Development executive at Vertex Pharmaceuticals, Amgen and Eli Lilly. She has made major contributions to >30 clinical programs in neurology, pain and psychiatry and to four marketed drugs for Cystic Fibrosis. Dr. Hoffman received her A.B. in Molecular Biology from Wellesley College and a Ph.D. in Cell Biology from the Johns Hopkins University.

Back to YC companies